At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 649 enrolled
Drug / intervention
Remdesivir +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Randomized, Double-Blind, Multicenter Study to Evaluate the Efficacy and Safety of Remdesivir Plus Tocilizumab Compared With Remdesivir Plus Placebo in Hospitalized Patients With Severe COVID-19 Pneumonia
In Brief
A Phase 3 clinical trial evaluating Remdesivir, Tocilizumab, and 1 other intervention for COVID-19 Pneumonia. Completed, enrolled 649 participants across 54 sites in 4 countries.
Detailed Summary
This study will evaluate the efficacy and safety of combination therapy with remdesivir plus tocilizumab compared with remdesivir plus placebo in hospitalized patients with COVID-19 pneumonia.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19 Pneumonia
CountriesBrazil, Russia, Spain, United States
CollaboratorsGilead Sciences
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartJun 2020
Primary CompletionFeb 2021
Study CompletionMar 2021
TodayJul 2026
First PostedJun 1, 2020
Enrollment StartJun 16, 2020
Primary CompletionFeb 1, 2021
Study CompletionMar 8, 2021
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 6.1 years ago
Interventions
Remdesivirdrug
Participants will receive intravenous (IV) RDV
Tocilizumabdrug
Participants will receive IV TCZ
Placebodrug
Participants will receive IV placebo matched to TCZ